Protagonist Therapeutics, Inc.
PTGXNASDAQHealthcare● Active
$98.08
+$0.70(+0.72%)
Market Cap$6.3B
P/E Ratio—
52W High$107.84
52W Low$49.38
Protagonist Therapeutics, Inc. (PTGX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PTGX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $46.02M | $434.43M | $60.00M | $26.58M | $27.36M |
| Cost of Revenue | $1.23M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $44.79M | $434.43M | $60.00M | $26.58M | $27.36M |
| Gross Margin %(computed) | 97.34% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $159.29M | $138.13M | $120.16M | $126.22M | $126.01M |
| G&A Expenses | $44.85M | $43.46M | $33.49M | $31.74M | $27.20M |
| Total Operating Expenses | $202.92M | $181.59M | $153.65M | $157.95M | $153.20M |
| Operating Income | ($158.13M) | $252.84M | ($93.65M) | ($131.37M) | ($125.84M) |
| Operating Margin %(computed) | -343.63% | 58.20% | -156.09% | -494.24% | -460.01% |
| Interest Income | $28.79M | $26.32M | $14.90M | $4.06M | $0.44M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($129.31M) | $279.41M | ($78.95M) | ($127.39M) | ($125.55M) |
| Income Tax Expense | $0.84M | $4.22M | $0.00M | $0.00M | $0.00M |
| Net Income | ($130.15M) | $275.19M | ($78.95M) | ($127.39M) | ($125.55M) |
| Net Margin %(computed) | -282.83% | 63.34% | -131.59% | -479.26% | -458.94% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.05 | $4.47 | $-1.39 | $-2.52 | $-2.65 |
| Wtd Avg Shares | 63.57M | 61.57M | 56.76M | 49.04M | 46.32M |
| EBITDA | ($128.09M) | $253.67M | ($90.34M) | ($128.00M) | ($123.07M) |
| EBITDA Margin %(computed) | -278.35% | 58.39% | -150.57% | -481.56% | -449.87% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Protagonist Therapeutics, Inc. data
About Protagonist Therapeutics, Inc. (PTGX) Income Statement
Protagonist Therapeutics, Inc. (PTGX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, PTGX reported revenue of $0.05B, gross profit of $0.04B (gross margin 97.34%), and net income of ($0.13B) — a net profit margin of -282.83%.
Frequently asked questions
PTGX · 4 questionsProtagonist Therapeutics, Inc. (PTGX) reported revenue of $0.05B for 2025, down 89.4% year-over-year.
PTGX revenuePTGX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08